FOX RUN MANAGEMENT, L.L.C.
Position in RARE — Ultragenyx Pharmaceutical Inc.
CIK 1533457
GREENWICH, CT
Position in RARE
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$777,999
+$63,329 QoQ
Shares Held
37,136
+56.3% QoQ
Ownership
0.038%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2021
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in RARE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026FOX RUN MANAGEMENT, L.L.C. holds $18,757,602 across 55 Biotechnology names. RARE ranks #3 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
18,715 | $897,758 | |
| 2 | NUVL |
Nuvalent, Inc.
|
8,173 | $837,323 | |
| 3 | RARE |
Ultragenyx Pharmaceutical Inc.
This page
|
37,136 | $777,999 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
10,778 | $696,582 | |
| 5 | SLNO |
Soleno Therapeutics Inc
|
19,934 | $667,390 | |
| 6 | ADMA |
Adma Biologics, Inc.
|
73,991 | $666,658 | |
| 7 | ONC |
BeOne Medicines Ltd.
|
2,136 | $634,327 | |
| 8 | ELVN |
Enliven Therapeutics, Inc.
|
15,573 | $610,461 |
All Filings in RARE
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $777,999 | 37,136 | Shares | Sole | 2026-05-12 | |
| 2025-09-30 | $714,670 | 23,759 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $606,812 | 16,689 | Shares | Sole | 2025-08-06 | |
| 2023-06-30 | $225,437 | 4,887 | Shares | Sole | 2023-08-11 | |
| 2022-09-30 | $553,030 | 13,355 | Shares | Sole | 2022-11-07 | |
| 2022-03-31 | $391,567 | 5,392 | Shares | Sole | 2022-05-10 | |
| 2021-06-30 | $511,457 | 5,364 | Shares | Sole | 2021-08-05 | |
| No filing history on record for this holder in this stock. | ||||||